Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Non-cash Items (2021 - 2025)

SAB Biotherapeutics' Non-cash Items history spans 5 years, with the latest figure at $26.1 million for Q4 2025.

  • For Q4 2025, Non-cash Items rose 2098.01% year-over-year to $26.1 million; the TTM value through Dec 2025 reached $26.1 million, up 2098.01%, while the annual FY2025 figure was $26.1 million, 2098.01% up from the prior year.
  • Non-cash Items reached $26.1 million in Q4 2025 per SABSW's latest filing, up from $11.8 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $26.1 million in Q4 2025 to a low of $109891.0 in Q4 2022.
  • Average Non-cash Items over 5 years is $6.0 million, with a median of $5.2 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: crashed 98.33% in 2022, then soared 2098.01% in 2025.
  • A 5-year view of Non-cash Items shows it stood at $6.6 million in 2021, then plummeted by 98.33% to $109891.0 in 2022, then skyrocketed by 505.12% to $664967.0 in 2023, then surged by 78.36% to $1.2 million in 2024, then skyrocketed by 2098.01% to $26.1 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Non-cash Items are $26.1 million (Q4 2025), $11.8 million (Q3 2025), and $5.2 million (Q2 2025).